Therapy for cutaneous T-cell lymphoma using low-dose bexarotene combined with phototherapy or alpha-interferon: Report of eight cases treated in Hospital Nacional Edgardo Rebagliati-Martins, Lima, Peru between 2003 and 2007
Descripción del Articulo
Introduction: Bexarotene is a rexinoid compound that is approved for use in the therapy for early and advanced stage cutaneous T-cell lymphoma (CTCL).Clinical Cases: We present in this report the results of the use of low-dose bexarotene plus phototherapy or alpha-interferon, nine...
| Autores: | , , , , , , , |
|---|---|
| Formato: | artículo |
| Fecha de Publicación: | 2018 |
| Institución: | Colegio Médico del Perú |
| Repositorio: | Acta Médica Peruana |
| Lenguaje: | español |
| OAI Identifier: | oai:amp.cmp.org.pe:article/2643 |
| Enlace del recurso: | https://amp.cmp.org.pe/index.php/AMP/article/view/2643 |
| Nivel de acceso: | acceso abierto |
| Materia: | linfoma cutáneo de células T bexaroteno interferon alfa Cutaneous T-cell lymphoma bexarotene alpha-interferon |
| id |
REVCMP_278770ecd7597d22e82d2bdc0d2f2e69 |
|---|---|
| oai_identifier_str |
oai:amp.cmp.org.pe:article/2643 |
| network_acronym_str |
REVCMP |
| network_name_str |
Acta Médica Peruana |
| repository_id_str |
. |
| spelling |
Therapy for cutaneous T-cell lymphoma using low-dose bexarotene combined with phototherapy or alpha-interferon: Report of eight cases treated in Hospital Nacional Edgardo Rebagliati-Martins, Lima, Peru between 2003 and 2007Tratamiento del linfoma cutáneo de células T con bexaroteno a dosis bajas en combinación con fototerapia o interferon alfa: comunicación de ocho casos tratados en el Hospital Edgardo Rebagliati Martins, 2003-2007, Lima, PerúBeltrán Gárate, BradyParedes Arcos, AntonioMoisés Alfaro, CeliaSanchez Félix, GadwinRiva Gonzales, LuisHurtado de Mendoza, FernandoCotrina Montenegro, EstherSalas Rojas, RenzoBeltrán Gárate, BradyParedes Arcos, AntonioMoisés Alfaro, CeliaSanchez Félix, GadwinRiva Gonzales, LuisHurtado de Mendoza, FernandoCotrina Montenegro, EstherSalas Rojas, Renzolinfoma cutáneo de células Tbexarotenointerferon alfaCutaneous T-cell lymphomabexarotenealpha-interferonIntroduction: Bexarotene is a rexinoid compound that is approved for use in the therapy for early and advanced stage cutaneous T-cell lymphoma (CTCL).Clinical Cases: We present in this report the results of the use of low-dose bexarotene plus phototherapy or alpha-interferon, nine million units, in the treatment of CTCL. Eight patients were treated, five had mycosis fungoides, two had CD-8 epidermothropic aggressive lymphoma. The overall response rate was 62.5% (5/8), and the mean duration of response was 20 months. Low-dose bexarotene combined with phototherapy or alpha-interferon may be effective in the treatment of CTCL.Introducción: bexaroteno es un rexinoide aprobado en el tratamiento de estadios tempranos y avanzados del linfoma cutáneo de células T (LCCT).Caso Clínico: el presente reporte de casos mostramos los resultados del empleo de bexaroteno en dosis bajas más fototerapia o Interferon alfa 9 millones en el tratamiento del LCCT. Ocho pacientes fueron tratados, cinco fueron Micosis fungoides, dos Linfoma Epidermotrópico CD8 agresivo y uno fue un Síndrome Sézary. La respuesta global fue del 62.5% (5/8) y la duración media de respuesta fue de 20 meses. El bexaroteno en dosis bajas en combinación a fototerapia o interferon alfa 2a puede ser efectivo en el tratamiento del LCCT.Colegio Médico del Perú2018-06-30info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://amp.cmp.org.pe/index.php/AMP/article/view/2643ACTA MEDICA PERUANA; Vol. 25 No. 4 (2008); 232-235ACTA MEDICA PERUANA; Vol. 25 Núm. 4 (2008); 232-2351728-59171018-8800reponame:Acta Médica Peruanainstname:Colegio Médico del Perúinstacron:CMPspahttps://amp.cmp.org.pe/index.php/AMP/article/view/2643/1540Copyright (c) 2023 ACTA MEDICA PERUANAinfo:eu-repo/semantics/openAccessoai:amp.cmp.org.pe:article/26432023-07-06T05:52:11Z |
| dc.title.none.fl_str_mv |
Therapy for cutaneous T-cell lymphoma using low-dose bexarotene combined with phototherapy or alpha-interferon: Report of eight cases treated in Hospital Nacional Edgardo Rebagliati-Martins, Lima, Peru between 2003 and 2007 Tratamiento del linfoma cutáneo de células T con bexaroteno a dosis bajas en combinación con fototerapia o interferon alfa: comunicación de ocho casos tratados en el Hospital Edgardo Rebagliati Martins, 2003-2007, Lima, Perú |
| title |
Therapy for cutaneous T-cell lymphoma using low-dose bexarotene combined with phototherapy or alpha-interferon: Report of eight cases treated in Hospital Nacional Edgardo Rebagliati-Martins, Lima, Peru between 2003 and 2007 |
| spellingShingle |
Therapy for cutaneous T-cell lymphoma using low-dose bexarotene combined with phototherapy or alpha-interferon: Report of eight cases treated in Hospital Nacional Edgardo Rebagliati-Martins, Lima, Peru between 2003 and 2007 Beltrán Gárate, Brady linfoma cutáneo de células T bexaroteno interferon alfa Cutaneous T-cell lymphoma bexarotene alpha-interferon |
| title_short |
Therapy for cutaneous T-cell lymphoma using low-dose bexarotene combined with phototherapy or alpha-interferon: Report of eight cases treated in Hospital Nacional Edgardo Rebagliati-Martins, Lima, Peru between 2003 and 2007 |
| title_full |
Therapy for cutaneous T-cell lymphoma using low-dose bexarotene combined with phototherapy or alpha-interferon: Report of eight cases treated in Hospital Nacional Edgardo Rebagliati-Martins, Lima, Peru between 2003 and 2007 |
| title_fullStr |
Therapy for cutaneous T-cell lymphoma using low-dose bexarotene combined with phototherapy or alpha-interferon: Report of eight cases treated in Hospital Nacional Edgardo Rebagliati-Martins, Lima, Peru between 2003 and 2007 |
| title_full_unstemmed |
Therapy for cutaneous T-cell lymphoma using low-dose bexarotene combined with phototherapy or alpha-interferon: Report of eight cases treated in Hospital Nacional Edgardo Rebagliati-Martins, Lima, Peru between 2003 and 2007 |
| title_sort |
Therapy for cutaneous T-cell lymphoma using low-dose bexarotene combined with phototherapy or alpha-interferon: Report of eight cases treated in Hospital Nacional Edgardo Rebagliati-Martins, Lima, Peru between 2003 and 2007 |
| dc.creator.none.fl_str_mv |
Beltrán Gárate, Brady Paredes Arcos, Antonio Moisés Alfaro, Celia Sanchez Félix, Gadwin Riva Gonzales, Luis Hurtado de Mendoza, Fernando Cotrina Montenegro, Esther Salas Rojas, Renzo Beltrán Gárate, Brady Paredes Arcos, Antonio Moisés Alfaro, Celia Sanchez Félix, Gadwin Riva Gonzales, Luis Hurtado de Mendoza, Fernando Cotrina Montenegro, Esther Salas Rojas, Renzo |
| author |
Beltrán Gárate, Brady |
| author_facet |
Beltrán Gárate, Brady Paredes Arcos, Antonio Moisés Alfaro, Celia Sanchez Félix, Gadwin Riva Gonzales, Luis Hurtado de Mendoza, Fernando Cotrina Montenegro, Esther Salas Rojas, Renzo |
| author_role |
author |
| author2 |
Paredes Arcos, Antonio Moisés Alfaro, Celia Sanchez Félix, Gadwin Riva Gonzales, Luis Hurtado de Mendoza, Fernando Cotrina Montenegro, Esther Salas Rojas, Renzo |
| author2_role |
author author author author author author author |
| dc.subject.none.fl_str_mv |
linfoma cutáneo de células T bexaroteno interferon alfa Cutaneous T-cell lymphoma bexarotene alpha-interferon |
| topic |
linfoma cutáneo de células T bexaroteno interferon alfa Cutaneous T-cell lymphoma bexarotene alpha-interferon |
| description |
Introduction: Bexarotene is a rexinoid compound that is approved for use in the therapy for early and advanced stage cutaneous T-cell lymphoma (CTCL).Clinical Cases: We present in this report the results of the use of low-dose bexarotene plus phototherapy or alpha-interferon, nine million units, in the treatment of CTCL. Eight patients were treated, five had mycosis fungoides, two had CD-8 epidermothropic aggressive lymphoma. The overall response rate was 62.5% (5/8), and the mean duration of response was 20 months. Low-dose bexarotene combined with phototherapy or alpha-interferon may be effective in the treatment of CTCL. |
| publishDate |
2018 |
| dc.date.none.fl_str_mv |
2018-06-30 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
https://amp.cmp.org.pe/index.php/AMP/article/view/2643 |
| url |
https://amp.cmp.org.pe/index.php/AMP/article/view/2643 |
| dc.language.none.fl_str_mv |
spa |
| language |
spa |
| dc.relation.none.fl_str_mv |
https://amp.cmp.org.pe/index.php/AMP/article/view/2643/1540 |
| dc.rights.none.fl_str_mv |
Copyright (c) 2023 ACTA MEDICA PERUANA info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
Copyright (c) 2023 ACTA MEDICA PERUANA |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Colegio Médico del Perú |
| publisher.none.fl_str_mv |
Colegio Médico del Perú |
| dc.source.none.fl_str_mv |
ACTA MEDICA PERUANA; Vol. 25 No. 4 (2008); 232-235 ACTA MEDICA PERUANA; Vol. 25 Núm. 4 (2008); 232-235 1728-5917 1018-8800 reponame:Acta Médica Peruana instname:Colegio Médico del Perú instacron:CMP |
| instname_str |
Colegio Médico del Perú |
| instacron_str |
CMP |
| institution |
CMP |
| reponame_str |
Acta Médica Peruana |
| collection |
Acta Médica Peruana |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1847149921875001344 |
| score |
13.955691 |
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
